Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

BPV9NO

PreclinicalSmall molecule

SSeoul Medical Center

BPV9NO is one of 2 small molecule programs targeting Hyperbaric Bupivacaine. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hyperbaric BupivacaineCompleted

Hyperbaric BupivacainePreclinical

Completed

Competition

Competitive Landscape

6 competitors in Hyperbaric Bupivacaine

#DrugCompanyPhaseTrials

Hyperbaric Bupivacaine

TTanta University

BPV9NO

SSeoul Medical Center

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperbaric Bupivacaine1 trial

Effect of Body-mass Index (BMI) on Median Effective Dose of Intrathecal Hyperbaric Bupivacaine

Completed·SSeoul Medical Center·N/A·NCT01291186·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BPV9NO. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BPV9NO compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BPV9NO. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSeoul Medical Center

Related News